Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
200000
sharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 12th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) issued through a third-party allotment
Who receives how much
Shares delivered during the month: 200,000 shares (200,000 new shares and 0 treasury shares transferred)
EVO FUND (issued on 8 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to exercise restrictions arising from exercises during the month: 3.1% (200,000 shares delivered / 6,544,419 listed shares as of the issuance and payment date)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥150 (floor exercise price)
Number of Stock Acquisition Rights
60,000 rights issued in total, 34,840 unexercised as of the end of the preceding month, 0 unexercised as of month-end (0 shares)
Reason for acquisition without consideration
Acquired without consideration and cancelled on 28 October 2026 (details of the acquisition conditions are Not disclosed in this document)
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Announced on 21 November 2025: issuance through a third-party allotment of new shares, the 12th stock acquisition rights (with an exercise price adjustment clause), the 13th stock acquisition rights and the 1st unsecured straight corporate bonds (private placement to a limited number of investors) (individual amounts are Not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 12th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) issued through a third-party allotment |
| Number of shares to be issued or disposed of | Shares delivered during the month: 200,000 shares (200,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 8 December 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions arising from exercises during the month: 3.1% (200,000 shares delivered / 6,544,419 listed shares as of the issuance and payment date) |
| Total number of issued shares | 9,360,419 shares (as of the end of the preceding month) → Not disclosed |
| Exercise price | ¥150 (floor exercise price) |
| Number of Stock Acquisition Rights | 60,000 rights issued in total, 34,840 unexercised as of the end of the preceding month, 0 unexercised as of month-end (0 shares) |
| Reason for acquisition without consideration | Acquired without consideration and cancelled on 28 October 2026 (details of the acquisition conditions are Not disclosed in this document) |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Announced on 21 November 2025: issuance through a third-party allotment of new shares, the 12th stock acquisition rights (with an exercise price adjustment clause), the 13th stock acquisition rights and the 1st unsecured straight corporate bonds (private placement to a limited number of investors) (individual amounts are Not disclosed) |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status and compliance with exercise restrictions.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.